Why VLA and not BNO???

Shareholders in BNO must be bitterly disappointed and asking themselves how come Merck has bit for Viralytics and not for Bionomics.

After all the hype about how much Merck "loves" us, Merck appears to have gotten all they want for absolute peanuts compared to the offer for Viralytics.

It also brings into question whether Bionomics itself still has control of anything of value.

The complete lack of interest in Bionomics after this bid for Viralytics speaks volumes as to the actual value of what is in our company - and it is not encouraging.

Perhaps I am just a stale bull - perhaps I am right.

It begs the question of why Bionomics does not simply market itself to Merck - a 160% premium to th eVWAP over the last month would get us out at 60c.

Does anyone else have any insights or better ideas ion how shareholders can get their money back with a modest gain for all the waiting and delays.

Is there reason for hope that we can get more than 60c for our shares in the foreseeable future?

I am over it.......